A joint research team from the Korea Advanced Institute of Science and Technology (KAIST) and biotechnology firm Neogenlogic has announced the development of an AI cancer vaccine model designed to support the creation of customised cancer vaccines using artificial intelligence.

According to Yonhap News Agency, the AI cancer vaccine platform identifies neoantigens that are unique to individual cancer patients. These neoantigens allow vaccines to train the immune system and help prevent cancer recurrence.

The researchers explained that neoantigens are mutation-derived protein fragments specific to a patient’s tumor. These fragments act as biological markers used by vaccines to activate immune responses.

While existing cancer vaccines primarily focus on stimulating cytotoxic T cells for immediate tumor attack, the team reported that emerging clinical evidence highlights the importance of B cell-mediated immune memory. This approach is associated with long-term antitumor protection and reduced recurrence risk.

The team revealed that its AI model predicts which neoantigens can trigger a strong B cell response. It does so by learning structural interaction patterns between mutant peptides and B cell receptors.

According to the researchers, the study introduces the world’s first AI framework capable of predicting both B cell immunogenicity and T cell responses. This capability is expected to improve the design of AI cancer vaccine strategies.

Key highlights include:

• AI cancer vaccine model identifies patient-specific neoantigens
• Platform predicts B cell and T cell immune responses
• Research supports long-term cancer recurrence prevention through immunotherapy

The findings were reported as part of ongoing efforts to apply artificial intelligence to precision oncology and vaccine development.

Related post

View all